DiaMedica Therapeutics Inc.
NASDAQDiaMedica Therapeutics just crossed two catalysts in 48 hours, and short sellers are watching carefully. Q1 2026 results, released after market close on May 6, came in at -$0.19 per share — inline with expectations. That matched but did not beat, which matters for a clinical-stage name trading almost entirely on pipeline momentum. Simultaneously, the European Stroke Organisation…
Snapshot as of 7 May 2026
DiaMedica Therapeutics just crossed two catalysts in 48 hours, and short sellers are watching carefully. Q1 2026 results, released after market close on May 6, came in at -$0.19 per share — inline with expectations.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DMAC — free to start on ORTEX.
Sign up for free →Open DMAC on ORTEX